Clinical trial
Long-term Outcome After Vemurafenib / BRAF Inhibitors Interruption in Erdheim-chester Disease
NCT02089724 is registered in ClinicalTrials.gov with Groupe Hospitalier Pitie-Salpetriere as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Long-term Outcome After Vemurafenib / BRAF Inhibitors Interruption in Erdheim-chester Disease
- Lead sponsor
- Groupe Hospitalier Pitie-Salpetriere
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- March 31, 2014
- Completion date
- April 30, 2019
- Enrollment
- 20 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.